Literature DB >> 17220327

Type-specific persistence of high-risk human papillomavirus infections in the New Independent States of the former Soviet Union Cohort Study.

Satu-Maria A Kulmala1, Irena P Shabalova, Nikolay Petrovitchev, Kari J Syrjänen, Ulf B Gyllensten, Bo C Johansson, Stina M Syrjänen.   

Abstract

BACKGROUND: Prospective follow-up studies have recently suggested that persistent high-risk human papillomavirus (HPV) infections play a key role in the progression of CIN lesions and in the development of cervical cancer. However, data on type-specific persistence, viral integration, and the role of multiple infections are scanty.
MATERIALS AND METHODS: A cross-sectional/cohort study was conducted between 1998 and 2002 in three New Independent States of the former Soviet Union comprising a cohort of 3,187 women, of whom 854 women were followed up for a mean of 17 months (SD, 11.6). HPV genotyping was done with real-time PCR, detecting HPV types 16, 18/45, 31, 33/52/58, 35, and 39. The integration status of HPV16 was examined by using a novel Taqman-based PCR method.
RESULTS: The mean clearance time for the individual high- risk-type infection was 16.5 months (range = 0.9-34.9 months). HPV16 and HPV31 were the most persistent infections (clearance times = 18.1 and 16.2 months, respectively), whereas HPV39 infections cleared most rapidly. The mean copies per cell in HPV18/45, HPV31, HPV33/52/58, and HPV39 infections were higher in persisting HPV infections than in HPV infections that cleared, but the difference was not significant. Integration of HPV16 was not found to correlate with HPV persistence.
CONCLUSIONS: A large proportion of women remained high-risk HPV positive after 18 months. Coinfection with multiple HPV types, viral load, or integration status did not correlate with persistence of high-risk HPV infections.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17220327     DOI: 10.1158/1055-9965.EPI-06-0649

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  18 in total

1.  Rates and determinants of incidence and clearance of cervical HPV genotypes among HIV-seropositive women in Pune, India.

Authors:  Arati Mane; Vikrant V Sahasrabuddhe; Amit Nirmalkar; Arun R Risbud; Seema Sahay; Ramesh A Bhosale; Sten H Vermund; Sanjay M Mehendale
Journal:  J Clin Virol       Date:  2016-10-28       Impact factor: 3.168

2.  P16 and Ki-67 expression improves the diagnostic accuracy of cervical lesions but not predict persistent high risk human papillomavirus infection with CIN1.

Authors:  Pingping Zhong; Jifeng Li; Yiqun Gu; Yu Liu; Aichun Wang; Yunfei Sun; Lijuan Lu
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

3.  Dynamics of genital human papillomavirus (HPV) infections among males eventually being uncovered.

Authors:  Kari Syrjänen
Journal:  Asian J Androl       Date:  2011-04-18       Impact factor: 3.285

4.  Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a µ genotype.

Authors:  Diane M Da Silva; Carly A Movius; Adam B Raff; Heike E Brand; Joseph G Skeate; Michael K Wong; W Martin Kast
Journal:  Virology       Date:  2014-02-17       Impact factor: 3.616

5.  Increase in viral load, viral integration, and gain of telomerase genes during uterine cervical carcinogenesis can be simultaneously assessed by the HPV 16/18 MLPA-assay.

Authors:  Wendy Theelen; Ernst-Jan M Speel; Michael Herfs; Martin Reijans; Guus Simons; Els V Meulemans; Marcella M Baldewijns; Frans C S Ramaekers; Joan Somja; Philippe Delvenne; Anton H N Hopman
Journal:  Am J Pathol       Date:  2010-09-02       Impact factor: 4.307

6.  Viral load in the natural history of human papillomavirus type 16 infection: a nested case-control study.

Authors:  Long Fu Xi; James P Hughes; Philip E Castle; Zoe R Edelstein; Chunhui Wang; Denise A Galloway; Laura A Koutsky; Nancy B Kiviat; Mark Schiffman
Journal:  J Infect Dis       Date:  2011-03-16       Impact factor: 5.226

7.  Reevaluation of epidemiological data demonstrates that it is consistent with cross-immunity among human papillomavirus types.

Authors:  David P Durham; Eric M Poolman; Yoko Ibuka; Jeffrey P Townsend; Alison P Galvani
Journal:  J Infect Dis       Date:  2012-08-07       Impact factor: 5.226

8.  Human papillomavirus (HPV) types 16, 18, 31, 45 DNA loads and HPV-16 integration in persistent and transient infections in young women.

Authors:  Agnihotram V Ramanakumar; Otelinda Goncalves; Harriet Richardson; Pierre Tellier; Alex Ferenczy; François Coutlée; Eduardo L Franco
Journal:  BMC Infect Dis       Date:  2010-11-11       Impact factor: 3.090

9.  Human Papillomavirus (HPV) type 16 and type 18 DNA Loads at Baseline and Persistence of Type-Specific Infection during a 2-year follow-up.

Authors:  Long Fu Xi; James P Hughes; Zoe R Edelstein; Nancy B Kiviat; Laura A Koutsky; Constance Mao; Jesse Ho; Mark Schiffman
Journal:  J Infect Dis       Date:  2009-12-01       Impact factor: 5.226

10.  Smoking is an independent risk factor for oncogenic human papillomavirus (HPV) infections but not for high-grade CIN.

Authors:  Kari Syrjänen; Irena Shabalova; Nicolay Petrovichev; Vladimir Kozachenko; Tatjana Zakharova; Julia Pajanidi; Jurij Podistov; Galina Chemeris; Larisa Sozaeva; Elena Lipova; Irena Tsidaeva; Olga Ivanchenko; Alla Pshepurko; Sergej Zakharenko; Raisa Nerovjna; Ludmila Kljukina; Oksana Erokhina; Marina Branovskaja; Maritta Nikitina; Valerija Grunberga; Alexandr Grunberg; Anna Juschenko; Rosa Santopietro; Marcella Cintorino; Piero Tosi; Stina Syrjänen
Journal:  Eur J Epidemiol       Date:  2007-09-08       Impact factor: 12.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.